Internal Medicine Department, Botucatu School of Medicine, São Paulo State University - UNESP
Botucatu, São Paulo, 18618-000, Brazil
NCT Number: NCT00564811
The aim of the study was to verify the influence of Agaricus blazei (Murrill) ss. Heinemann (A. blazei) on the evolution of nutritional state and liver function in hepatitis C patients.
Looking for future studies?
Notify Me24 year–70 year
All sexes
Interventional
Not applicable
Botucatu, São Paulo, 18618-000, Brazil
Ten patients were studied (5 - GI - not taking A. blazei - and 5 - G2 - taking A. blazei), from both sexes, with positive Anti-VHC and a healthy nutritional state, admitted into in the viral hepatitis ward. Diagnosis and treatment for hepatitis C concurred with the regulations of the Ministry of Health and nutritional evaluation was performed in 3 moments according to anthropometrical, bioimpedance, biochemical and dietary standards, with duration of 6 months. The consumption of A. blazei (10g/day) in dehydrated powder was concomitant with antiviral therapy (conventional or pegylated interferon associated with ribavirin) with duration of 5 months.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Agaricus blazei powder, 10 grams/day, for 5 months
Time frame: Time Frame: six months
UPECLIN HC FM Botucatu Unesp
Other
Effect of Agaricus Blazei (Murrill) ss. Heinemann (Sun Mushroom) on the Nutritional State and Liver Biochemistry in Hepatitis C Patients.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03219957
Blood-Borne Infections, Chronic Disease
Antwerp, Belgium
View Trial DetailsNCT02098616
Blood-Borne Infections, Chronic Disease
Long Beach, California, United States
View Trial DetailsNCT01808248
Blood-Borne Infections, Chronic Disease
San Antonio, Texas, United States
View Trial DetailsNCT03935906
Blood-Borne Infections, Communicable Diseases
Melbourne, Australia
View Trial Details